4-(benzo[d][1,3]dioxol-5-yl)-3,7,7-trimethyl-6,7,8,9-tetrahydro-1H-pyrazolo[3,4-b]quinolin-5(4H)-one | 865658-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 4-(benzo[d][1,3]dioxol-5-yl)-3,7,7-trimethyl-6,7,8,9-tetrahydro-1H-pyrazolo[3,4-b]quinolin-5(4H)-one
• 英文别名: 4-(1,3-benzodioxol-5-yl)-3,7,7-trimethyl-2,4,6,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-5-one
• CAS: 865658-70-4
• 化学式: C₂₀H₂₁N₃O₃
• 分子量: 351.405
• InChiKey: BEOOLTINJRWUPV-UHFFFAOYSA-N

物化性质

• 沸点：
  535.9±50.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• KINASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Wagner Florence Fevrier

  公开号：US20140107141A1

  公开（公告）日：2014-04-17

  The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.

  本发明提供了I式化合物，其药学上可接受的盐和药物组合物。本发明的化合物有用于抑制激酶（例如GSK3（例如GSK3α或GSK3β）或CK1）活性。本发明还提供了使用本文所述化合物治疗激酶介导的疾病的方法，例如神经系统疾病、精神障碍、代谢性疾病和癌症。
• Kinase inhibitors and methods of use thereof
  申请人：The Broad Institute, Inc.

  公开号：US10137122B2

  公开（公告）日：2018-11-27

  The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.

  本发明提供了式 I 的化合物、其药学上可接受的盐及其药物组合物。本发明化合物可用于抑制激酶（如 GSK3（如 GSK3α 或 GSK3β）或 CK1）活性。本发明进一步提供了使用本文所述化合物治疗激酶介导的疾病，如神经系统疾病、精神疾病、代谢紊乱和癌症的方法。
• GSK3 INHIBITORS AND METHODS OF USE THEREOF
  申请人：The Broad Institute, Inc.

  公开号：EP2909204B1

  公开（公告）日：2018-12-05
• USES OF PARALOG-SELECTIVE INHIBITORS OF GSK3 KINASES
  申请人：The Broad Institute, Inc.

  公开号：US20160375006A1

  公开（公告）日：2016-12-29

  The present disclosure provides methods of using GSK3α-selective inhibitors for treating Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder. The GSK3α-selective inhibitors include compounds of Formula I-A. The present disclosure also provides methods of using GSK3β-selective inhibitors for treating a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder. The GSK3β-selective inhibitors include compounds of Formula I-B.
• US9096594B2
  申请人：——

  公开号：US9096594B2

  公开（公告）日：2015-08-04